Get the Stockscreener App
29.49
4.61%
1.30
Gh Research Plc stock is traded at $29.49, with a volume of 233.47K.
It is up +4.61% in the last 24 hours and up +10.16% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$28.19
Open:
$28.31
24h Volume:
233.47K
Relative Volume:
0.79
Market Cap:
$2.02B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-37.33
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
-2.58%
1M Performance:
+10.16%
6M Performance:
+100.61%
1Y Performance:
+130.84%
1-Day Range:
$28.25
$30.19
1-Week Range:
$28.05
$30.96
52-Week Range:
$11.83
$31.44
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
29.49 | 2.08B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan
Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC (GHRS) director receives 2,202 fully vested share options - Stock Titan
GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike - Stock Titan
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
GH Research (NASDAQ:GHRS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
FY2026 EPS Estimates for GH Research Boosted by Analyst - MarketBeat
Trading the Move, Not the Narrative: (GHRS) Edition - Stock Traders Daily
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com UK
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative? - Sahm
GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen - MarketBeat
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com India
GH Research (NASDAQ:GHRS) Reaches New 12-Month High Following Earnings Beat - MarketBeat
GH Research stock hits all-time high at 31.41 USD - Investing.com
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
GH Research PLC (GHRS) Stock Analysis: A Biotech Powerhouse with 30.55% Upside Potential - directorstalkinterviews.com
GH Research PLC (GHRS) Stock News Today - tradingkey.com
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
GH Research PLC Stock 12‑Month Price Target Raised to $41.1, Implies 41% Upside - TradingView
Needham & Company LLC Raises GH Research (NASDAQ:GHRS) Price Target to $39.00 - MarketBeat
GH Research PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GHRS: GH001 achieves rapid, sustained TRD remission with fewer visits and robust IP protection - TradingView
GH Research (Nasdaq: GHRS) grows cash to $362.7M as R&D spending rises - Stock Titan
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
GH Research Q2 FY26 net loss widens to $15.1 million - Bitget
GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development work - Bitget
GH Research (NASDAQ:GHRS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Is GH Research (GHRS) Trading At A Premium To Fair Value? - Yahoo Finance
Is GH Research (GHRS) Fully Valued Following Its Share Price Surge? - Sahm
(GHRS) Volatility Zones as Tactical Triggers - Stock Traders Daily
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GH Research (NASDAQ:GHRS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
GHRS|GH Research PLC|Price:27.830|Chg%:+0.550 - TradingKey
GH Research PLC (GHRS) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GHRS Initiated Coverage by Wells Fargo -- Price Target Announced at $44 - GuruFocus
GH Research PLC (GHRS) Institutional Confidence - TradingKey
Troluce Capital Advisors LLC Raises Holdings in GH Research PLC $GHRS - MarketBeat
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GHRS|GH Research PLC|Price:27.280|Chg%:-0.350 - TradingKey
GH Research PLC (GHRS) Cash Flow - TradingKey
GHRS|GH Research PLC|Price:28.070|Chg%:-0.310 - TradingKey
GH Research PLC Revenue Breakdown – NASDAQ:GHRS - TradingView
GH Research PLC (GHRS) Income Statement - TradingKey
GH Research PLC (GHRS) Balance Sheet - TradingKey
GHRS: GH Research PLC Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - marketscreener.com
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):